Results 61 to 70 of about 9,765 (234)

Charakterisierung des Lipidbindungsverhaltens und der Proteinfaltung von HCV NS5A unter Einfluss des NS5A-Inhibitors Daclatasvir [PDF]

, 2021
Mit 71 Millionen chronisch erkrankten Patienten im Jahr 2015 stellt die chronische Hepatitis C-Virusinfektion eine wichtige Ursache für Zirrhose, Leberdekompensation und Leberkrebs dar. Eine grundlegende Eigenschaft des Hepatitis C-Virus (HCV) ist die Biogenese modifizierter intrazellulärer Membranen.
openaire   +2 more sources

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors [PDF]

ACS Medicinal Chemistry Letters, 2013
The discovery of potent thienoimidazole-based HCV NS5A inhibitors is herein reported. A novel method to access the thienoimidazole [5,5]-bicyclic system is disclosed. This method gave access to a common key intermediate (6) that was engaged in Suzuki or Sonogashira reactions with coupling partners bearing different linkers.
Simon, Giroux, Jinwang, Xu, T Jagadeeswar, Reddy, Mark, Morris, Kevin M, Cottrell, Caroline, Cadilhac, James A, Henderson, Oliver, Nicolas, Darius, Bilimoria, Francois, Denis, Nagraj, Mani, Nigel, Ewing, Rebecca, Shawgo, Lucille, L'Heureux, Subajini, Selliah, Laval, Chan, Nathalie, Chauret, Francoise, Berlioz-Seux, Mark N, Namchuk, Anne-Laure, Grillot, Youssef L, Bennani, Sanjoy K, Das, John P, Maxwell   +22 more
openaire   +2 more sources

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection [PDF]

, 2015
published_or_final_versio
Abergel, A, Agarwal, K, Asselah, T, Brainard, DM, Chan, HLY, Feld, JJ, Gruener, N, Hézode, C, Jacobson, IM, Lai, CL, Mangia, A, Mazzotta, F, McHutchison, JG, McNally, J, Moreno, C, Osinusi, A, Ruane, PJ, Shafran, SD, Svarovskaia, E, Towner, WJ, Tran, TT, Yoshida, E, Zeuzem, S, Zhu, Y   +23 more
core   +1 more source

Identification and Characterization of an In Silico Designed Membrane‐Active Peptide with Antiviral Properties

Advanced Science, Volume 13, Issue 16, 18 March 2026.
An evolutionary molecular dynamics platform is used to design P1.6, a membrane‐active peptide that senses lipid packing defects in viral envelopes. P1.6 adopts a stabilized α‐helical structure upon membrane contact, disrupts virus‐like liposomes, and damages HIV‐1 particles.
Pascal von Maltitz, Niek van Hilten, Tatjana Weil, Thunchanok Thummaraj, Jeroen Methorst, Dennis Aschmann, Alexander Kros, Clarissa Read, Jasmina Gačanin, Herre Jelger Risselada, Jan Münch   +10 more
wiley   +1 more source

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology Journal, 2017
Background In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained ...
Leen Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere, René Verloes, Sandra De Meyer   +5 more
doaj   +1 more source

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Health Science Reports, 2023
Background and Aim Management of genotype 4 hepatitis C virus (HCV) has shifted to interferon‐free regimens with a high sustained virological response (SVR‐12), especially with NS5B/NS5A inhibitor combinations such as sofosbuvir and ledipasvir (Sof‐Led).
Hala Joharji, Delal Alkortas, Aziza Ajlan, Mohamed Ahmed, Hamad Al‐Ashgar, Mohammed Al‐Quaiz, Dieter Broering, Mohammed Al‐Sebayel, Hussien Elsiesy, Faisal A. Alkhail, Waleed K. Al‐Hamoudi, Edward De Vol, Epi Amirah Almuhayshir, Ahmed Al‐Jedai   +13 more
doaj   +1 more source

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection

Frontiers in Public Health, 2022
BackgroundIncreased interferon (IFN)-gamma inducible protein-10 (IP-10) level has been shown to be associated with sustained virologic responses (SVRs) to pegylated interferon-alpha 2a/ribavirin-based therapy in patients with chronic hepatitis C (CHC ...
Yadong Wang, Yangyang Hu, Xing Zhang, Yue Luo, Luyuan Ma, Jingjing Lu, Qianfei Liang, Chengjun Xu, Caiyan Zhao, Calvin Q. Pan, Calvin Q. Pan   +10 more
doaj   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, Volume 46, Issue 2, Page 475-512, March 2026.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source

Targeting a host-cell entry factor barricades antiviral-resistant HCV variants from on-therapy breakthrough in human-liver mice [PDF]

, 2015
Objective: Direct-acting antivirals (DAAs) inhibit hepatitis C virus (HCV) infection by targeting viral proteins that play essential roles in the replication process. However, selection of resistance-associated variants (RAVs) during DAA therapy has been
Ball, Jonathan K., Baumert, Thomas, Bhuju, Sabin, Brown, Richard J.P., Cortese, Riccardo, Doerrbecker, Juliane, Farhoudi, Ali, Geffers, Robert, Leroux-Roels, Geert, McClure, C. Patrick, Mesalam, Ahmed Atef, Meuleman, Philip, Nicosia, Alfredo, Pietschmann, Thomas, Troise, Fulvia, Van Den Eede, Naomi, Vercauteren, Koen, Verhoye, Lieven   +17 more
core   +4 more sources